Background: House dust mite (HDM) respiratory allergy is a common and burdensome
| INTRODUCTION
Allergic rhinitis is estimated to affect 17%-29% of the population across Europe 1 and is found in all ethnic groups and ages. A survey of children and adolescents found that allergies generally had significant negative effects on physical and mental health compared to children/ adolescents without allergies with 40% of parents, indicating that allergies affected their child's school performance and 21% reported their child's work or other activities were limited by allergies. 2 Allergy to house dust mite (HDM) is prevalent in children and adolescents and has notable clinical implications. allergen extracts. 4 Recently, new trials with sublingual tablet formulations examining dosing, treatment onset, effect size, and quality of life in both patients with allergic rhinitis and allergic asthma have been conducted. 4 The SQ HDM SLIT-tablet (ALK, Denmark) is a once-daily fastdissolving formulation (oral lyophilisate) containing standardized HDM allergen extract. SQ HDM SLIT-tablets have demonstrated clinical benefit in adults with HDM allergic rhinitis (with or without conjunctivitis) and HDM allergic asthma. [5] [6] [7] [8] [9] [10] [11] One safety trial conducted in adolescents found that SQ HDM SLIT-tablets were well tolerated. 12 Among trials that evaluated the efficacy and safety of SQ HDM SLITtablet for the treatment of moderate-severe HDM allergic rhinitis, 2 trials included adolescent subpopulations (aged 12-17 years). 5, 6 The objective of this post hoc analysis was to use pooled data from these 2 previously published trials to evaluate the efficacy and safety of SQ HDM SLIT-tablets in the adolescent subpopulation.
| METHODS

| Trial designs
Two randomized, parallel-group, double-blind, placebo-controlled, multisite, phase 3 trials were conducted investigating the efficacy and safety of the SQ HDM SLIT-tablet in HDM allergic subjects. One trial was conducted in North America (trial A; clinicaltrials.gov identifier NCT01700192) and 1 trial was conducted in Japan (trial B; JapicCTI number 121848). Both trials have been previously described. 5, 6 The trials were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.
| Subject selection criteria
Subjects in both trials were adolescents and adults (12-85 years of age in trial A and 12-64 years of age in trial B) with a history of moderatesevere HDM allergic rhinitis and with a history of prior pharmacologic treatment for HDM allergic rhinitis in the previous year before the screening visit.
In trial A, subjects were required to be sensitized to HDM with a positive skin test ≥5 mm compared with saline control and serum specific 
| Treatment
The SQ HDM SLIT-tablet is a rapidly dissolving freeze-dried tablet and Der p 2 combined). 13 The first tablet was administered at the trial site followed by a 30-minute observation period; subsequent self-administrations were at-home. In trial A, subjects were randomized 1:1 to once-daily treat- Open-label symptom-relieving medications were provided by the trial sponsors and allowed in trial A when a minimum symptom threshold was met or persistent eye symptoms were present, and in trial B when subjects felt that symptoms were intolerable. Per US FDA regulatory requirement epinephrine auto-injectors were provided to subjects in trial A.
| Assessments
The primary end-point in both trials was the average total combined rhinitis score (TCRS) during the last 8 weeks of treatment. TCRS was the sum of the rhinitis DSS and rhinitis daily medication score (DMS) with a range of 0-24 points. The rhinitis DSS was the sum of four nasal symptoms (runny nose, blocked nose, sneezing and itchy nose), each rated on a scale from 0 (no symptoms) to 3 (severe symptoms) with a range of 0-12 points. The rhinitis DMS consisted of symptomatic medication scores with a range of 0-12. Secondary end-points were rhinitis DSS, conjunctivitis DSS (sum of gritty feeling/red/itchy eyes and watery eyes) rated on a scale of 0-3, rhinitis DMS and conjunctivitis DMS (range of 0-8). Details of symptom and medication scoring have been previously described. 5, 6 Rhinitis exacerbation days were defined as days with an allergic rhinitis symptom score of 6, or 5 with one individual symptom scored 3 (ie, implying a symptom that was hard to tolerate and caused interference with activities of daily living and/or sleeping). Mild days were defined as days with no individual symptom scored higher than 1 (ie, the symptom was clearly present but caused minimal awareness and was easily tolerated) and no antihistamine use. 
| Statistical analysis
The primary efficacy analysis was conducted on the full analysis 
| RESULTS
| Adolescent subgroup
In all, 1482 subjects were randomized in trial A, including 189 adolescents; 946 subjects were randomized in trial B, including 302 adolescents. The pooled adolescent FAS was comprised of 395 adolescents (N=201, 12 SQ HDM; N=194, placebo; see subject disposition in Figure 1 ). Slightly more subjects discontinued from the 12 SQ HDM group (n=27; 13%) than from the placebo group (n=19; 10%); the difference was explained by more AEs leading to discontinuation (n=11; 5% vs n=3; 2%).
Demographics and baseline characteristics for the pooled adolescent subpopulation are shown in Table 1 
| Efficacy assessments
In the pooled adolescent subpopulation, the average TCRS based on adjusted means was significantly improved with 12 SQ HDM vs placebo (treatment difference of −1.04; P<.01; 
| Safety
The safety profiles for the two complete trial populations have been previously described. 5, 6 No new safety signals were identified in the adolescent subpopulation. More subjects in the active group reported treatment-related AEs; however, the majority were mild in intensity (Table 3) . Less than 1% of the AEs reported by adolescent subjects were assessed as severe (7 events in the 12 SQ HDM group and 3 events in the placebo group). Two subjects treated with 12 SQ HDM reported 5 severe AEs that were assessed as treatment-related; the events were nausea, oral pruritus (2 events in 1 subject), tongue pruritus and throat irritation. There were no treatment-related SAEs reported in the adolescent subpopulation and no severe local swellings and no adolescent subjects were treated with epinephrine due to AEs. One event of anaphylactic reaction was reported in the adolescent subpopulation; this concerned a 16-year-old male from the 12 SQ HDM group who experienced moderate throat swelling after consuming a cookie. The event occurred 2 days after discontinuation of treatment (on day 16 due to an AE of mouth ulceration) and was assessed as unrelated to treatment. The event was treated with diphenhydramine hydrochloride and resolved within 60 minutes.
SQ HDM (N=201) Placebo (N=194)
Number of subjects with event (%)
Number of events (%)
Number of subjects with event (%) AE, adverse event; N, number of subjects in safety set; SAEs, serious AEs, defined according to ICH Harmonised Tripartite Guideline E2A, Step 5.
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Note that solicited and unsolicited AEs were pooled for this summary.
T A B L E 3 Overall summary of AEs for adolescent subjects treated with placebo or 12 SQ HDM (safety set)
The most common treatment-related AEs were oral pruritus (reported by 45% of subjects in the active group vs 8% in placebo), throat irritation (40% vs 19%) and ear pruritus (27% vs 6%; Table 4 ).
| DISCUSSION
Sublingual allergy immunotherapy with SQ HDM SLIT-tablet was clinically effective and well tolerated in adolescents with moderatesevere HDM allergic rhinitis. The efficacy and safety in the adolescent subpopulation appear to be comparable to the total trial population. 5, 6 The improvement in the TCRS in adolescents is considered clinically relevant as defined by the World Allergy Organization definition 15 and as predefined in the trial by Demoly et al. 7 Significant improvements in rhinitis DSS, rhinitis DMS and conjunctivitis DSS were also observed with 12 SQ HDM treatment. Furthermore, the treatment reduced the patient's probability for having rhinitis exacerbation days and increased the probability for having mild days with no more than minimal awareness of symptoms, parameters that are perhaps more tangible for patients to understand. The observed improvements are especially notable when considering all subjects, including those in the placebo group, were allowed to use allergy symptom-relieving medications throughout the trials. On that note, a meta-analysis of pharmacotherapies and SQ HDM SLIT-tablets found that nasal symptoms due to perennial allergens were only improved 3.7% with a leukotriene receptor antagonist, 4.8% with an oral antihistamine and 11.2% with an inhaled corticosteroid, whereas the SQ HDM SLIT-tablet improved nasal symptoms by 16.1%. 16 Thus, the SQ HDM SLIT-tablet appears to provide clinically relevant benefits for adolescents with HDM allergy.
The current pooled results confirm the results of a phase 1 adolescent safety trial that determined the most common AEs with SQ HDM SLIT-tablet were oral pruritus and throat irritation. 12 There is no difference between current pooled data and the phase 1 trial when observed events and their intensities were compared. However, many of the most common treatment-related AEs were reported at a higher incidence in the pooled analysis compared with the phase 1 trial, which is likely due to the use of solicited AEs in trial A. 17, 18 The side effect report card actively solicited the presence or absence of local AEs and resulted in higher proportions of subjects reporting specific
AEs compared with previous SLIT-tablet trials. 5 In contrast, the phase 1 adolescent trial and trial B used spontaneous AE reporting, resulting in similar AE reporting frequencies.
The efficacy results from this pooled analysis including subjects Allergy immunotherapy is the only treatment modality with the capability to change the natural course of the allergic disease, thereby preventing its exacerbation 19 and the possible progression from allergic rhinitis to asthma symptoms. 20, 21 Further, not well-controlled allergic rhinitis reduces sleep quality impairing concentration, school attendance and performance, 22 highlighting the importance of treating allergic rhinitis effectively in adolescents.
A limitation of the current analyses is that the inclusion criteria for the two trials differed in relation to requirements of a higher level of serum specific IgE and a positive nasal provocation test in trial B. This could lead to a more sensitive population as data with grass sublingual immunotherapy have suggested a trend towards higher efficacy in subjects with higher pre-treatment specific IgE levels. 23 In addition, the analyses were performed post hoc and as such should be interpreted with caution. More information on the efficacy of allergy immunotherapy in children and adolescents with HDM allergic asthma and HDM allergic rhinitis would be of interest.
In conclusion, this post hoc analysis suggests that sublingual allergy immunotherapy with the SQ HDM SLIT-tablet (12 SQ HDM dose) is effective with a clinically relevant magnitude of effect, and well tolerated in adolescents with moderate-severe HDM allergic rhinitis.
T A B L E 4 Summary by SOC and PT of the most frequent treatment-related AEs (≥5% of subjects in the 12 SQ HDM group; safety set) e, number of events; N, number of subjects in safety set; n, number of subjects with event; %n, percentage of subjects in safety set with the event; PT, preferred term; SOC, system organ class. Note that solicited and unsolicited AEs were pooled for this summary. a A cognitive debriefing study suggested that subjects might have misinterpreted the solicited question (have you experienced tongue ulcer/sore on the tongue) as tongue pain rather than an actual ulcer. 
